For example, recombinant IL-33 (rIL-33) treatment can exacerbate cisplatin-induced acute kidney injury by increasing CD4+ T cell infiltration, CXCL1 production, and acute tubular necrosis [27]. Here, IL33 is linked to acute kidney injury.